What is INBEC Tablet?

INBEC Tablet is a prescription antiretroviral medicine containing a fixed combination of abacavir, dolutegravir, and lamivudine. The product is used as part of antiretroviral therapy for the management of HIV-1 infection. The three active ingredients belong to two major groups of HIV medicines: dolutegravir is an integrase strand transfer inhibitor (INSTI), while abacavir and lamivudine are nucleoside analogue reverse transcriptase inhibitors (NRTIs).

Each tablet contains 600 mg of abacavir, 50 mg of dolutegravir, and 300 mg of lamivudine.

HIV attacks cells of the immune system and uses specific enzymes to reproduce itself. The medicines in INBEC work at different stages of the HIV replication process. By combining three antiretroviral agents in one tablet, the medicine forms part of a combination treatment approach designed to suppress HIV replication.

INBEC should only be used when prescribed by a qualified healthcare professional. The choice of antiretroviral treatment depends on factors such as the person’s medical history, previous HIV treatment, resistance profile, kidney and liver function, other medicines, and relevant laboratory tests.

INBEC Tablet Uses

INBEC is used as part of antiretroviral treatment for HIV-1 infection. Combination therapy helps reduce HIV replication and supports maintenance of immune-system function.

Commonly recognized therapeutic use includes:

• Treatment of HIV-1 infection as part of an appropriate antiretroviral regimen.
• Suppression of HIV replication when the combination is considered appropriate by a healthcare professional.
• Long-term management of HIV infection under specialist medical supervision.

INBEC is not a cure for HIV and should not be considered a replacement for comprehensive HIV care.

INBEC Tablet Benefits

The potential clinical benefits of an appropriate abacavir, dolutegravir, and lamivudine regimen include:

• Helps suppress HIV replication.
• Combines three antiretroviral medicines in a fixed-dose formulation.
• Supports long-term HIV disease management.
• Dolutegravir targets HIV integrase, an enzyme required for viral replication.
• Abacavir and lamivudine interfere with HIV reverse transcriptase, another enzyme needed for viral replication.

Treatment response varies between individuals. Regular medical follow-up and appropriate laboratory monitoring are important parts of HIV care.

How Does INBEC Work?

INBEC works through three active ingredients with complementary mechanisms.

Dolutegravir belongs to the integrase strand transfer inhibitor class. It blocks HIV integrase, an enzyme HIV requires to insert its genetic material into human cells. Inhibiting this process helps prevent the virus from continuing its replication cycle.

Abacavir and lamivudine are nucleoside analogue reverse transcriptase inhibitors. They interfere with reverse transcriptase, an HIV enzyme needed to make viral DNA. By interfering with this process, these medicines help limit the production of new HIV virus.

Using medicines that target different stages of HIV replication is an important principle of combination antiretroviral therapy.

General Information About INBEC Dosage

INBEC is a prescription medicine and its dosage must be determined by the treating healthcare professional. Patients should not independently change the amount, frequency, or duration of treatment.

The fixed-dose formulation may not be appropriate for every patient because individual components may require adjustment in certain medical situations. Current prescribing information specifically highlights considerations involving kidney and liver function and certain concomitant medicines.

Never start, stop, or modify HIV treatment without medical advice.

INBEC Tablet Side Effects

Like all medicines, INBEC may cause side effects, although not everyone experiences them.

Common or Possible Side Effects

Depending on the individual and the overall treatment regimen, possible adverse effects may include:

• Headache
• Nausea
• Diarrhea
• Difficulty sleeping
• Tiredness or fatigue
• Dizziness
• Abdominal discomfort

The occurrence and severity of side effects can vary from person to person.

Serious Side Effects

Abacavir-containing medicines can cause a serious hypersensitivity reaction, which can potentially be life-threatening. People with the HLA-B*5701 allele have a higher risk, and appropriate screening is recommended before starting abacavir-containing treatment.

INBEC also requires particular attention in people who have hepatitis B because stopping lamivudine-containing treatment can be associated with worsening hepatitis B in people with HIV/HBV coinfection.

Seek urgent medical attention if a severe or unusual reaction develops.

Warnings and Precautions

Before treatment with INBEC, the healthcare professional should know about:

• Previous allergy or hypersensitivity to abacavir or any component of the medicine.
• HLA-B*5701 status.
• Liver disease or hepatitis B infection.
• Kidney problems.
• Previous HIV treatment and possible drug resistance.
• Other prescription or non-prescription medicines being taken.
• Pregnancy or plans to become pregnant.
• Any significant medical conditions.

Because dolutegravir and the other components can interact with certain medicines, a complete medication history is important.

Patients should also follow their healthcare professional’s advice regarding alcohol and activities requiring alertness if they experience dizziness or other symptoms that could affect concentration.

Drug Interactions

INBEC can interact with other medicines. Important interactions may occur with certain medicines that affect drug metabolism or absorption.

Patients should tell their healthcare professional about all:

• Prescription medicines
• Over-the-counter medicines
• Vitamins and minerals
• Herbal products
• Supplements

Some medicines and mineral-containing products can affect dolutegravir absorption or blood concentrations. A healthcare professional can determine whether medicines need to be separated, changed, or monitored.

Storage Instructions

Store INBEC according to the conditions stated on its packaging or product information.

General precautions include:

• Keep the tablets in their original packaging where appropriate.
• Protect the medicine from excessive heat and moisture.
• Keep away from direct sunlight.
• Keep out of reach of children.
• Do not use tablets after the expiry date.
• Do not use damaged or visibly altered tablets.

INBEC Tablet Price and Manufacturer

The INBEC manufacturer identified for this product is Emcure Pharmaceuticals Ltd. The photographed pack contains 30 tablets.

The INBEC price may vary according to pack, location, pharmacy, applicable regulations, and pricing updates. Current pricing should be confirmed through an authorized pharmacy or the manufacturer’s current product information rather than relying on an outdated online listing.

Disclaimer

This information is provided for general educational purposes and should not be considered a substitute for professional medical advice. INBEC is a prescription antiretroviral medicine and should be used only under the supervision of a qualified healthcare professional.

Do not self-medicate, discontinue HIV treatment, or change treatment based solely on information found online. Individual treatment decisions depend on clinical history, laboratory results, HIV resistance information, other medicines, and other patient-specific factors.

Frequently Asked Questions

1. What is INBEC Tablet used for?

INBEC contains abacavir, dolutegravir, and lamivudine and is used as part of antiretroviral treatment for HIV-1 infection. It works by targeting different processes required for HIV replication. Treatment should be selected and monitored by a qualified healthcare professional.

2. What are the active ingredients in INBEC?

INBEC contains three active ingredients: abacavir 600 mg, dolutegravir 50 mg, and lamivudine 300 mg per tablet. These medicines belong to antiretroviral classes that work at different stages of HIV replication.

3. How does INBEC work?

Dolutegravir inhibits HIV integrase, while abacavir and lamivudine interfere with HIV reverse transcriptase. Blocking these viral enzymes helps suppress HIV replication.

4. Is INBEC a cure for HIV?

No. INBEC is an antiretroviral treatment used to control HIV replication. HIV requires ongoing medical management, and treatment should be continued according to the healthcare professional’s recommendations.

5. What are the common INBEC side effects?

Possible side effects can include headache, nausea, diarrhea, fatigue, dizziness, abdominal discomfort, and sleep-related problems. Not everyone experiences side effects, and their severity can vary.

6. Is there an important warning associated with abacavir?

Yes. Abacavir can cause a potentially serious hypersensitivity reaction. HLA-B*5701 screening is recommended before initiating abacavir-containing treatment because people with this allele have a higher risk.

7. Can INBEC be used by someone with hepatitis B?

HIV and hepatitis B coinfection requires careful medical management. Because lamivudine is active against hepatitis B, stopping a lamivudine-containing regimen can lead to worsening hepatitis B. Patients with hepatitis B should therefore be medically monitored.

8. Can INBEC interact with other medicines?

Yes. INBEC can interact with other medicines, including some medicines that affect dolutegravir concentrations or absorption. Patients should provide their healthcare professional with a complete list of medicines, supplements, vitamins, and herbal products.

9. Can INBEC be stopped without medical advice?

No. HIV treatment should not be stopped or changed without guidance from the treating healthcare professional. Stopping treatment can have important consequences for HIV management and, in people with HIV/HBV coinfection, may also affect hepatitis B.

10. Who should supervise INBEC treatment?

INBEC should be prescribed and monitored by a qualified healthcare professional experienced in HIV treatment. The appropriate regimen depends on the individual’s medical history, laboratory results, previous treatment, possible resistance, and other medicines.